Clinical Trial Update: Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV [Phase 3]

View source ↗

Summary

Phase 3 trial investigating valganciclovir to prevent CMV organ damage in people with HIV has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infections
• HIV Infection

Drugs mentioned

• Valganciclovir (Valganciclovir)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Cytomegalovirus Infections, HIV Infections | Phase 3 | Status: COMPLETED